Metabolon Launches New Drug Discovery Service
Posted September 20, 2006
RESEARCH TRIANGLE PARK, N.C. — Metabolon
is augmenting its product offerings with mSelect, a system based on metabolomic analysis that can detect drug-induced biochemical changes.
Metabolomics is the study of small molecules, such as glucose and cholesterol, that are produced by cellular metabolism. The metabolome is the catalog of those molecules in a specific organism.
Metabolon's new program is designed to help companies discover the most promising and lowest-risk drug candidates.
"mSelect enables researchers in the early stages of drug discovery to prioritize lead candidates so the most viable compounds can be advanced with confidence," said John Ryals, chief executive officer of Metabolon. "Unlike the results obtained from the targeted approaches offered in current solutions, mSelect analyzes activity across virtually the entire spectrum of pathways in a single test. Our mSelect solution gives a clear, comprehensive assessment of compound activity that allows drug developers to make informed decisions about the direction of their research."
Metabolon's patented technology can analyze effects of compounds on cells.